MENU
OPTH
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

OPTH stock forecast, quote, news & analysis

Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector... Show more

OPTH
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for OPTH with price predictions
Jul 31, 2026

OPTH saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for OPTH moved out of overbought territory on July 21, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 54 similar instances where the indicator exited the overbought zone. In of the 54 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OPTH as a result. In of 131 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

OPTH moved below its 50-day moving average on July 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OPTH crossed bearishly below the 50-day moving average on July 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPTH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for OPTH entered a downward trend on July 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OPTH advanced for three days, in of 202 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OPTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.811) is normal, around the industry mean (47.256). P/E Ratio (0.000) is within average values for comparable stocks, (103.786). OPTH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.832). OPTH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (94.340) is also within normal values, averaging (115.273).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.1B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 19%. BHC experienced the highest price growth at 56%, while BIOA experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 32% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 63
Price Growth Rating: 59
SMR Rating: 88
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
OPTH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Details
OPTH saw its Stochastic Oscillator peaks and leaves the overbought zone